New cargo results released delivering Cre enzyme, page-30

Apologies, had the previous post in the wrong thread title.

In previous announcements, the company has mentioned that it hopes to include more automation, so that it can screen more FPPs, make the throughput faster and that they're working with CROs and other collaborators to get their expertise and potentially even have access to different scaffolds that they can develop themselves.

That's interesting. On the Operational Update Investor Call dated 13 February, 2018 Peptidream was mentioned.

Few points that stood out for me from that call...

* The company highlighted that Peptidream is a therapuetic peptide discovery platform.
* That they effectively produce peptide libraries.
* That they have potentially trillions of hits that they can garner from their libraries.
* But the most important point that stood out for me was that they have a highly automated system which enables them to screen and get results within around four hours (as they say). Why was that interesting for me? If that's the case, couldn't Phylogica actually be complimentary to Peptidream's platform, because if Peptidream can find the drugs and Phylogica's intracellular FPP technology could potentially be the delivery mechanism, then what a complimentary match that could be. Add to that, Phylogica can also tap into their own platform for therapeutic target themselves.

Tony